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Introduction Left atrial (LA) remodeling is a key determinant of atrial fibrillation (AF) ablation 35 
outcome. Optimal methods to assess this process are scarce. LA sphericity is a shape-based 36 
parameter shown to be independently associated to procedural success. In a multicenter 37 
study, we aimed to test the feasibility of assessing LA sphericity and evaluate its capability to 38 
predict procedural outcomes. 39 
Methods This study included consecutive patients undergoing first AF ablation during 2013. A 40 
3D model of the LA chamber, excluding pulmonary veins and LA appendage, was used to 41 
quantify LA volume and sphericity (≥82.1% was considered spherical LA). 42 
Results In total, 243 patients were included across 9 centers (71% men, aged 56±10 years, 44% 43 
with hypertension and 76% CHA2DS2-VASc≤1). Most patients had paroxysmal AF (66%) and 44 
underwent radiofrequency ablation (60%). Mean LA diameter, volume, and sphericity were 45 
42±6mm, 100±33ml, and 82.6±3.5%, respectively. Adjusted Cox models identified paroxysmal 46 
AF (HR 0.54, p=0.032) and LA sphericity (HR 1.87, p=0.035) as independent predictors for AF 47 
recurrence. A combined clinical-imaging score (LAGO) including 5 items (AF phenotype, 48 
structural heart disease, CHA2DS2-VASc≤1, LA diameter and LA sphericity) classified patients at 49 
low (≤2 points) and high risk (≥3 points) of procedural failure (35% vs 82% recurrence at 3-year 50 
follow-up, respectively; HR 3.10, p<0.001).  51 
Conclusion In this multicenter, real-life cohort, LA sphericity and AF phenotype were the 52 
strongest predictors of AF ablation outcome after adjustment for covariates. The LAGO score 53 
was easy to implement, identified high risk of procedural failure, and could help select optimal 54 
candidates. 55 
 56 
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CONDENSED ABSTRACT 59 
In this multicenter, real-life cohort (243 patient, 9 centers) demonstrates LA sphericity (HR 60 
1.87) and AF phenotype (HR 0.54) as the strongest predictors of AF ablation outcome after 61 
adjustment for covariates. A new clinical-imaging score (LAGO) identified high risk of 62 
procedural failure (HR 3.10), and could help select optimal candidates. 63 
  64 
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WHAT’S NEW? 65 
- AF ablation success is highly dependent on atrial disease stage. Methods to assess LA 66 
remodeling are crucial to determine disease progression and help to select optimal 67 
candidates. 68 
- LA sphericity is a shape-based remodeling parameter independent of size. In a single 69 
center MRI study was found to be associated to procedural success. 70 
- The present study demonstrates, in a multicenter fashion, LA sphericity as the only 71 
imaging parameter with independent predictive value for recurrence after first AF 72 
ablation, after adjusting for covariates, regardless of AF phenotype, imaging modality, 73 
energy source, and center experience.  74 
- We propose a simple clinical-imaging “LAGO” score that easily identified patients at 75 
high risk of procedural failure, and could be clinically useful to select optimal 76 




Ablation has become the cornerstone of treatment for symptomatic atrial fibrillation (AF).1 79 
However, patient outcomes differ significantly depending on clinical characteristics and AF 80 
phenotype.2 Recent evidence supports that left atrial (LA) remodeling is the most important 81 
factor in procedural success.3 Methods to assess LA remodeling have evolved substantially, 82 
allowing deeper characterization of this progressive disease. The use of M-mode LA diameter 83 
(LAD) as the standard to evaluate LA remodeling has been progressively abandoned.4 Instead, 84 
3D imaging modalities have been shown to better define chamber volumes and shape, the 85 
presence and extent of myocardial fibrosis, and, with speckle tracking, the functional status of 86 
the LA.5–8 Most of these parameters, however, are confined to the research field.  87 
Left atrial sphericity, defined as the variation between actual LA shape and a perfect sphere, 88 
was first described in a single center MRI study as a new shape-based remodeling parameter 89 
strongly and independently associated to procedural failure: the higher the LA sphericity, the 90 
higher the probability of recurrence.8  91 
The aim of the study was to test the feasibility of assessment in a multicenter study (including 92 





Study Design 96 
This was a multicenter, observational study of a cohort of consecutive patients undergoing a 97 
first ablation procedure for paroxysmal and persistent AF. The main objective was to validate 98 
at multiple centers the predictive value of LA sphericity, assessed by 3D imaging, in the 99 
outcomes of AF ablation.  100 
Study Population 101 
The study included patients from January 1 to December 31, 2013, who underwent a first 102 
ablation of symptomatic drug-refractory paroxysmal and persistent AF. Three-dimensional 103 
imaging of the LA was acquired prior to the procedure with computed tomography (CTA) or 104 
magnetic resonance angiograms (MRA). Patients with previous catheter or surgical LA ablation 105 
were excluded. 106 
Minimum requirements for participating centers included a minimum of 25 AF ablations/year, 107 
pulmonary vein isolation (PVI) as procedural endpoint (radiofrequency or cryoenergy), pre-108 
procedural 3D imaging in at least 50% of procedures, and data collection on baseline, 109 
procedural, and follow-up variables of interest in prospective institutional databases. All 110 
patients must have given consent for their inclusion in institutional databases. Nine out of 16 111 
centers screened met these criteria and participated in the study. Centers were categorized as 112 
high (≥100 AF ablations/year) or low (<100 AF ablations/year) volume according to previous 113 
literature.9 114 
A dataset of 10 MRA of non-AF volunteers was analyzed to explore LA spherical deformation in 115 
young, healthy individuals. Details of this population were previously reported.10 116 
The study protocol was approved by the hospitals’ Ethics Committee. 117 
3D image postprocessing 118 
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Each center applied institutional acquisition protocols for pre-procedural CTA or MRA; 119 
postprocessing, previously described in detail,8 was centralized in a single center. In summary, 120 
a 3D reconstruction of LA cavity (CT and MR) was created with the CARTO 3® (Biosense 121 
Webster, Diamond Bar, CA, USA) image integration plug-in after excluding PVs and LA 122 
appendage at their ostia. The resulting 3D model was imported to ADAS-AF™ (Galgo Medical, 123 
Barcelona, Spain) to calculate remodeling values including LA volume (LAV) and sphericity. 124 
Quantification of LA remodeling parameters was blinded to clinical and ablation data.  125 
Conceptually, LA sphericity quantifies the variation between the LA shape and a perfect sphere 126 
(Figure 1). Detailed mathematical formulae have been thoroughly specified in previous 127 
publications.8 Briefly, LA sphericity is the coefficient of variation of the sphere (CVS), a non-128 
dimensional parameter (independent of size) that captures the shape by dividing the standard 129 
deviation of the average radius (AR) of the sphere by the AR. The AR is calculated as the mean 130 
of distances between all points of the LA wall (3D model) and the center of the LA. To facilitate 131 
understanding of the value, it is expressed as a percentage: (1- CVS)*100. 132 
The aim of the study was to test the validity of LA sphericity categories in an external, 133 
heterogeneous, real-life cohort. For this purpose, the same cutoff values of the seminal paper 134 
were used to define spherical categories: Group 1 ≤ 82.1% < Group 2 < 85.7% ≤ Group 3.  135 
Ablation procedure 136 
Ablation was performed according to institutional protocols for paroxysmal and persistent AF, 137 
which included both contact and non-contact force sensing catheters, as well as first and 138 
second generation cryoballoon technologies. All centers using point-by-point radiofrequency 139 
ablation reported using wide antral circular ablation to achieve PVI.  140 
All patients underwent pre- and postprocedural oral anticoagulation (international normalized 141 
ratio between 2 and 3) for at least 1 month before and after ablation. As a general rule, 142 
antiarrhythmic drugs (AAD) were discontinued ≥5 half-lives before ablation (or ≥1 week for 143 
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amiodarone). In the majority of cases, transesophageal echocardiography was performed 144 
before ablation to exclude the presence of LA thrombus. After transseptal puncture, a bolus of 145 
i.v. heparin was administered according to patient weight, followed by additional 146 
boluses/continuous infusion to maintain an activated clotting time of 250-350 seconds.  147 
Radiofrequency ablation began with a 3D map using an electroanatomic mapping system 148 
(CARTO, Biosense Webster, Diamond Bar, CA, USA or Ensite, St Jude Corporation, St Paul, MN, 149 
USA). In some cases, CTA or MRA were integrated into the navigation system to improve LA 150 
anatomic reconstruction. Wide encircling pulmonary vein ablation was performed using 151 
radiofrequency energy (open-irrigated tip catheter) assisted by a circular multipolar catheter. 152 
Additional ablation lines or ablation of complex fractioned electrograms were performed 153 
according to each hospital’s protocol.  154 
For cryoballoon ablation, an inner-lumen mapping catheter (Achieve™, Medtronic¸ 155 
Minneapolis, MN, USA) was advanced to each PV ostium through a steerable 15 Fr sheath 156 
(FlexCath Advance™, Medtronic) to monitor PV potentials. A 28-mm Cryoballoon (Arctic Front 157 
or Arctic Front Advance™, Medtronic) was advanced, inflated, and positioned at each PV 158 
ostium until optimal occlusion was achieved. Cryoenergy was then delivered up to 240 seconds 159 
to achieve PVI, applying a bonus freeze as a general rule. Cryoenergy at right-side pulmonary 160 
veins was applied under phrenic nerve monitoring by pacing at superior vena cava.  161 
Post-ablation management and follow-up 162 
Treatment with AAD during the first 3 months after ablation was prescribed according to 163 
physician preference. As a general rule, class IC drugs were first choice in patients with no 164 
structural heart disease and paroxysmal AF; class III were preferred in cases of structural heart 165 
disease or persistent AF. Continuation of AAD therapy beyond 3 months post-ablation was 166 
based on documented AF recurrence or symptoms without any documented atrial arrhythmia. 167 
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Patient follow-up included a minimum of 3 visits at the outpatient clinic (3, 6 and 12 months 168 
post-ablation) with 12-lead ECG and at least one 24-hour Holter monitoring. When available, a 169 
more prolonged rhythm monitoring was performed with 2-, 3- or 7-day Holter or implantable 170 
loop recorder (ILR, Reveal XT, Medtronic, MN). Between scheduled visits, patients were 171 
instructed to seek medical care, to include an ECG whenever they presented with symptoms. 172 
Primary endpoint was defined as any documented AF or flutter lasting more than 30 seconds 173 
by ECG, Holter or ILR during follow-up. No blanking period was considered after the ablation 174 
procedure.  175 
Statistical Analysis 176 
Continuous data are expressed as mean±SD, median, and interquartile range (IQR) or number 177 
(percentage) as appropriate. The χ2 or Fisher exact test was used to compare proportions 178 
between groups. Student t, Mann–Whitney U, one factor ANOVA, or Kruskal-Wallis tests were 179 
used to compare continuous variables between groups according to normality assumptions. 180 
Survival analysis using Cox proportional hazards model was used to identify univariate and 181 
multivariate predictors of AF recurrence after first AF ablation. A P-value of ≤0.05 was 182 
considered significant. Analysis was performed using SPSS 19.0 statistical package (SPSS, 183 




In total, 473 patients underwent AF ablation at the 9 participating centers in 2013. Three 186 
centers were categorized as high volume (33%). Patients undergoing repeat AF ablation, those 187 
with no or suboptimal pre-procedural imaging or with inadequate follow-up were excluded. A 188 
final cohort of 243 patients was included in the final dataset (Supplemental figure S1). Most 189 
patients had paroxysmal AF (66%) and low CHA2DS2-VASc scores (≤1 in 67%). Ablation was 190 
performed a median of 43 (24-72) months after AF diagnosis and radiofrequency was the most 191 
common energy source used for ablation (60%). There were 14 non-fatal complications (5.7%), 192 
due to vascular access complications (4), cardiac tamponades (3), pericarditis (3), and transient 193 
ischemic attack, phrenic nerve palsy, acute pulmonary edema, and hemoptysis (1 each). There 194 
were no deaths. Detailed baseline and procedural characteristics are listed in Table 1.   195 
After a median (IQR) follow-up of 457 (351-764) days, the overall recurrence rate after first 196 
procedure was 43.3%, occurring after a median (IQR) of 182 (92-367) days. Considering a 3-197 
month blanking period, the recurrence rate dropped to 34.8%, with a median (IQR) time-to-198 
recurrence of 305 (179-468) days (Supplemental figure S2). Three quarters of the patients 199 
received AAD during the first 3 months after ablation (class I in 63% of cases), and 39% of all 200 
patients received ongoing treatment (class I in 55% of cases). Repeat AF ablation was required 201 
in 17% of patients. 202 
Post-ablation rhythm monitoring was performed with 24-hour Holter in the majority of cases 203 
(72%). Longer monitoring was performed in 26%, including 2, 3, and 7-day Holter recordings 204 
and implantable loop recorders. Only 3 patients (1.2%) were monitored with ECG-only. 205 
Left Atrial Remodeling  206 
3D imaging was obtained with MRA in most cases (61%). Measurements of LA remodeling are 207 
detailed in Table 2. Mean LA sphericity was 82.6 ± 3.5% and most patients (59%) showed 208 
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spherical deformation (including groups 2 and 3). Healthy controls showed significantly lower 209 
mean LA sphericity and LAV (76.50±3.21 and 34.4±8.6ml, respectively; p<0.001). 210 
LA sphericity was weakly but significantly correlated with LAD (R=0.342; p<0.01) and LAV 211 
(R=0.327; p<0.001). Important collinearity was observed between LA sphericity and both LAD 212 
and LAV (eigenvalue of 0.001 and condition index 48).  213 
Probability of recurrence after first procedure was greater in patients with spherical LA (groups 214 
2 and 3) compared to those with discoid LA (group 1) after one (38% vs 25%), two (58% vs 215 
44%) and three (73% vs 47%) years of follow up (log rank p=0.026) (Figure 2). 216 
Patients with spherical LA had higher BMI and more dilated LA, and more often received 217 
ablation in high-volume centers (Table 3). Paradoxically, patients with a more spherical atrium 218 
had a lower proportion of high blood pressure and prior CV. It is noteworthy that AF 219 
phenotype and AF duration did not differ between LA sphericity groups, and no differences 220 
were observed in AAD use, cardioversion, or repeat ablation during follow-up. There was a 221 
higher proportion of non-paroxysmal AF in patients with dilated LA (43.3% vs 22.0% assessed 222 
by LAD, p=0.002 and 42.3% vs 26.9% assessed by LAV, p=0.012).  223 
Predictors of Ablation Outcome 224 
Univariate Cox regression analysis identified significant associations between adverse outcome 225 
after AF ablation and persistent AF, radiofrequency ablation, spherical LA, and dilated LA, 226 
whether assessed by LAD or volume. A trend toward increased risk of recurrence in patients 227 
with structural heart disease was also observed. Detailed description is provided in 228 
Supplemental Table S1. 229 
Multivariate Cox proportional hazard analysis was performed to identify independent risk 230 
factors for recurrence (Table 4). Seven variables with significant association in the univariate 231 
Cox models and other previously reported independent predictors were included: high-volume 232 
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centers, obesity, structural heart disease, CHA2DS2-VASc ≤1, AF phenotype, time since AF 233 
diagnosis, and energy source. Due to serious collinearity problems, five separate models were 234 
tested:  LA sphericity (model 1), LAV (model 2), LAD (model 3), both LA sphericity and LAD 235 
(model 4) and LA sphericity, LAV, and LAD (model 5). 236 
Paroxysmal AF and spherical remodeling were the only factors independently associated with 237 
recurrence across all models (HR ≈ 0.5 and HR ≈ 2, respectively). CHA2DS2-VASc (≤1) showed 238 
independent predictive value with a HR ≈ 0.5 when LAD was not included (models 1 and 2).  239 
Presence of structural heart disease remained significant only in model 1 (HR ≈ 2).  240 
LA dilation assessed by LAD was found to be independently associated with recurrence. When 241 
LA sphericity was included in the model, however, the significance did not persist. Remarkably, 242 
LAV was not associated with recurrence when adjusted for other covariates.  243 
New Scoring System to Predict Recurrences 244 
A new clinical- and imaging-based model for pre-procedural risk stratification (Left Atrial 245 
Geometry and Outcome [LAGO] score) was built upon the identified predictors of recurrence: 246 
AF phenotype, presence of structural heart disease, CHA2DS2-VASc ≤1, dilated LA, and spherical 247 
LA (scoring 1 point each). The area under the curve was 0.687 (95% CI 0.610-0.765; p<0.001). 248 
Cutoff point of 3 (LR+ of 3; sensitivity 21%, specificity 94%) was independently associated with 249 
recurrence (HR 3.10 [95% CI 1.94-4.95]; p<0.001) (Figure 3). Patients scoring ≤2 had better 250 
short- and mid-term outcome compared to those with ≥3 points (probability of recurrence of 251 
22% vs 50% at 1 year and 35% vs 82% at 3 years of follow-up).  252 
DISCUSSION 253 
To our knowledge, this is the first study to validate the value of LA sphericity in predicting AF 254 
ablation outcome in a multicenter cohort. The study had 3 main findings: 1) LA sphericity was 255 
the only remodeling parameter with independent predictive value for AF ablation outcome 256 
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regardless of AF phenotype, energy source, imaging modality, and operator experience; 2) 257 
Persistent AF was the only clinical factor associated with recurrences after adjustment for 258 
covariates; 3) A 5-item scoring system including clinical and imaging parameters better 259 
identified patients at very high risk of recurrence at mid-term follow-up. 260 
LA remodeling in AF 261 
Remodeling of the LA is the final pathway of a high number of cardiac diseases. Any condition 262 
generating volume or pressure overload of the LA could be considered a causal factor for AF 263 
development. In addition, AF itself promotes electrical, tissue, and structural changes of the 264 
LA, which promote the perpetuation of the arrhythmia (“AF begets AF”).11  265 
Structural remodeling has been classically defined as LA enlargement: both diameter and 266 
volume are increased in patients with AF, compared to those in sinus rhythm.12 However, 267 
although LA size (especially volume) was a strong predictor of cardiovascular outcomes in 268 
patients in sinus rhythm, the predictive value in patients with AF was poor.12   269 
The present study is the first to also provide LA shape analysis of a young, healthy population, 270 
allowing an approximation to normality of spherical deformation. As with size, LA sphericity 271 
was increased in patients with diagnosed AF, compared to healthy controls in sinus rhythm. 272 
However, conclusions on the impact of AF in spherical deformation cannot be drawn from this 273 
analysis. Further comparison adjusted for covariates is warranted. 274 
In our previous work,8 LA sphericity was shown to be associated with risk factors such as 275 
hypertension, sleep apnea, and presence of structural heart disease, as well as AF phenotype 276 
(higher sphericity in patients with non-paroxysmal AF). In another study, LA sphericity was 277 
strongly associated with thromboembolic events in patients with AF, compared to controls: 278 
the higher the spherical deformation the greater the likelihood of stroke.13  279 
In our cohort, all imaging parameters of LA remodeling were mildly but significantly correlated. 280 
It is noteworthy that AF phenotype was correlated with LA dilation but not with spherical 281 
deformation. This finding was confirmed in multivariate models, as both AF phenotype and LA 282 
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sphericity were independently associated with recurrence. Similar findings with LA fibrosis 283 
were observed in the multicenter DECAAF study,7 suggesting that degree of atrial remodeling 284 
is not necessarily related to a particular AF pattern. Although indication and predicted 285 
outcome for AF ablation is usually based on AF phenotype, the findings of our study and those 286 
of Marrouche et al encourage a more refined assessment of LA disease before deciding the 287 
best therapeutic strategy for each patient.  288 
AF Ablation Outcome 289 
Current guidelines recommend LA size quantification to assess the remodeling process 290 
associated with AF.1 In patients suitable for ablation due to symptomatic drug-refractory AF, 291 
an association between LA dilation and worse outcome has been suggested; however, due to 292 
the weakness of the evidence, current guidelines do not state any recommendation on 293 
patients’ suitability for ablation in terms of LA size.1 A recent meta-analysis evaluating 294 
individual baseline clinical and remodeling characteristics failed to find an association between 295 
LA size and recurrences.14 Better characterization of the remodeling process associated with 296 
AF beyond size is therefore needed to improve ablation results. Evidence on more refined LA 297 
structural and functional parameters is growing and demonstrates strong association with the 298 
likelihood of procedural success.6,7,15,16 299 
In this regard, previous single center series (106 patients) showed spherical deformation of the 300 
LA to be independently associated with the probability of recurrence after last AF ablation 301 
(mean of 1.4 procedures/patient).8 The main limitations of our previous series were the bias of 302 
a single, high-volume center with very experienced operators; single imaging modality (MRA); 303 
and not accounting for current state-of-the-art ablation tools (only radiofrequency without 304 
contact-force sensing was used). The present study was designed to overcome these 305 
limitations and test 3D-imaging remodeling predictors of AF ablation outcome after a first 306 
procedure in a multicenter cohort, including a wide spectrum of center profiles (low vs high 307 
volume, experienced vs less-experienced operators), different energy sources (cryoballoon vs 308 
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radiofrequency), and different imaging modalities (CT and MRI) to emulate real-life clinical 309 
practice. Demonstration of the independent predictive value of LA sphericity in this setting 310 
represents a clinically meaningful finding, providing strong evidence of its applicability in a 311 
wide range of clinical settings. 312 
Although LA size and recurrence were associated in univariate Cox analyses, both diameter 313 
and volume were rendered nonsignificant when adjusted for covariates. These findings mimic 314 
our previous report and those from Marrouche et al, suggesting that more advanced imaging 315 
characterization tools (LA sphericity or fibrosis) may be superior to size quantification alone for 316 
the precise definition of LA disease progression, and may better stratify risk of recurrence. 317 
Contrary to previous reports,17 the volume of AF ablation procedures per center/year did not 318 
impact outcome. 319 
Risk Prediction Scheme 320 
LAGO score is a simple risk prediction model that combines five clinical and imaging variables, 321 
each of which provides additive predictive value for AF recurrence. This allows easy 322 
identification of patients with high scores (≥3 points) who are unlikely to remain in sinus 323 
rhythm at 3-year follow-up (<15% likelihood), and for whom ablation should not be advised as 324 
a rhythm control strategy.  325 
Limitations 326 
The main limitation of the study is its retrospective nature; nevertheless, the baseline, 327 
procedural and follow-up data were extracted from prospective institutional databases.  328 
Image acquisition and ablation approach protocols were not homogeneous across centers. In 329 
our view, this constitutes a strength rather than a weakness of the study, as the results reflect 330 
the heterogeneous, real-life cases encountered in daily practice and confirms, to some extent, 331 
the broad applicability of LA sphericity. 332 
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Exclusion of patients due to incomplete baseline or follow-up data could introduce a selection 333 
bias; however, these exclusions were mostly driven by incomplete pre-procedural evaluation 334 
and follow-up from the referral physicians and was not necessarily related to specific patient 335 
profiles.  336 
CONCLUSION 337 
In this multicenter study, LA sphericity was the only imaging parameter with independent 338 
predictive value for recurrence after first AF ablation, after adjusting for covariates, regardless 339 
of AF phenotype, imaging modality, energy source, and center experience. The simple clinical-340 
imaging “LAGO” score easily identified patients at high risk of procedural failure, and could be 341 
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FIGURE LEGENDS 403 
Figure 1. Left atrial sphericity (LASP) categories: examples of discoid (A) and spherical-shaped 404 
LA (B) corresponding to low and high LASP, respectively. Posterior and right lateral views of 3D 405 
model are displayed. LAV, LA volume.  406 
Figure 2. Kaplan-Meier plot for AF-free survival by LA sphericity 407 
Figure 3. Kaplan Meier plot for AF-free survival by LAGO score (non-adjusted). Patients scoring 408 




Table 1. Baseline, procedural and follow-up patient characteristics 411 
 Mean ±SD / % 
Age 56.6 ± 9.7 
Sex (Male) 71.0 % 
BMI 27.8 ± 4.4 
Obesity (BMI >30) 27.8% 
HBP 107 ± 44.4 
DM 8.7 % 
SOAS 8.7 % 
SHD 16.3 % 
LVEF  61.5 ± 10.6 
Prior stroke 3.3 % 
CHA2DS2-VASc  (mean) 1.21 ± 1.17 
0 32.6 % 
1 34.3 % 
2 18.8 % 
3 9.2 % 
4 4.6 % 
≥5 0.4 % 




 Mean ±SD / % 
Paroxysmal AF 66.0 % 
AF duration (months) 43 ± 48 
Prior CV 27.8 % 
Energy source (RF) 60.3 % 
Ablation time (min) 33.3 ± 16.4 
PVI check 98.8 % 
Substrate ablation 7.1 % 
Procedural time (min) 190.6 ± 57.9 
Fluoroscopy time (min) 32.7 ± 26.7 
Complications 6.2 % 
AAD blanking 75.5 % 
Class I 63.4 % 
Class III 35.0 % 
Class I+III 1.6 % 
AAD post-blanking 38.6 % 
Class I 54.8 % 
Class III 44.1 % 
Class I+III 1.1 % 
CV follow-up 9.2 % 
Repeat AF ablation 17.1 % 
Follow-up Holter 24h 72.4 % 
Follow-up Holter ≥ 48h 26.4 % 
Follow-up ECG only 1.3 % 
 415 
Abbreviations: AF, atrial fibrillation; AAD, antiarrhythmic drug; BMI, body mass index; CV, 416 
cardioversion; DM, diabetes mellitus; HBP, high blood pressure; LVEF, left ventricular ejection 417 
fraction; PVI, pulmonary vein isolation; RF, radiofrequency; SOAS, sleep obstructive apnea 418 
syndrome; SHD, structural heart disease. 419 




Table 2. Left atrial remodeling parameters 422 
 Mean (SD) / % 
 
LAD (mm) 41.5 ± 5.9 
Dilated LA (by LAD) 43 % 
LAV 99.6 ± 33.4 
Dilated LA (by LAV) 46.1 % 
Indexed LAV 50.9 ± 16.4 
LA sphericity 82.62 ± 3.51 
Group 1 40.7 % 
Group 2 39.8 % 
Group 3 19.5 % 
Spherical LA 59.3 % 
Abbreviations: LA, left atrium; LAD, left atrial diameter; LAV, left atrial volume 423 
  424 
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Table 3. Baseline, procedural, and imaging characteristics, by LA sphericity group 425 
 426 
 DISCOID LA SPHERICAL LA  
 Mean ± SD / % Mean ± SD / % P value 
Age 56.4 ± 8,6 56.7 ± 10.5 0.786 
Sex (Male) 72.4% 69.9% 0.672 
BMI 26.9 ± 4.0 28.5 ± 4.6 0.015* 
Obesity 23.4% 31.3% 0.244 
HBP 52% 39.2% 0.048* 
SOAS 10% 7.7% 0.497 
SHD 14.3% 17.7% 0.478 
LVEF 61.1 ± 11.5 62.0 ± 9.1 0.533 
CHA2DS2-VASc ** 1 (0-2) 1 (0-2) 0.712 
CHA2DS2-VASc 0 30.1% 33.8% 0.642 
CHA2DS2-VASc ≤1 67.0% 66.9% 0.986 
    
Paroxysmal AF 70.4% 62.9% 0.229 
AF Time 56.3 ± 46.0 51.7 ± 41.1 0.433 
Prior CV 35.7% 23.0% 0.033* 
    
High-volume center 50% 69.2% 0.003* 
RF time 32.1 ± 13.5 34.3 ± 18.5 0.487 
Substrate ablation 5.1% 8.4% 0.327 
CV follow-up 6.1% 11.3% 0.175 
Repeat ablation 13.3% 19.7% 0.192 
AAD post-blanking 28.1% 33.8% 0.356 
    
LA sphericity 79.24 ± 2.49 84.94 ± 1.84 <0.001* 
LA diameter 39.5 ± 5.7 42.7 ± 5.7 <0.001* 
Dilated LA (by LA diameter) 42.1% 60.5% 0.012* 
LA volume 92.6 ± 28.4 104.4 ± 35.7 0.007* 
Dilated LA (by LA volume) 34.7% 53.8% 0.003* 
Indexed LA volume 47.9 ± 14.7 53.2 ± 17.4 0.034* 
Abbreviations as in table 1 and 2. *  Statistically significant, **U Mann-Whitney Test 427 
  428 
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Table 4. Multivariate Cox proportional hazard models for prediction of recurrences after AF 429 
ablation. 430 
 
MULTIVARIATE COX REGRESSION 
 
MODEL 1 MODEL 2 MODEL 3 MODEL 4 MODEL 5 
 
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P 
High-volume center 0.91 (0.52-1.58) 0.740 0.80 (0.47-1.38) 0.424 0.85 (0.46-1.57) 0.601 0.92 (0.50-1.70) 0.796 0.90 (0.49-1.66) 0.728 
Obesity 1.08 (0.64-1.84) 0.767 1.03 (0.61-1.75) 0.910 1.24 (0.68-2.28) 0.486 1.18 (0.65-2.14) 0.595 1.21 (0.66-2.23) 0.534 
SHD 2.06 (1.09-3.88) 0.026 1.75 (0.93-3.27) 0.082 1.36 (0.66-2.79) 0.402 1.69 (0.82-3.46) 0.155 1.63 (0.79-3.37) 0.188 
CHA2DS2-VASc ≤1 0.54 (0.32-0.92) 0.024 0.55 (0.32-0.94) 0.029 0.58 (0.33-1.02) 0.059 0.61 (0.35-1.07) 0.083 0.59 (0.33-1.03) 0.065 
Paroxysmal AF 0.51 (0.31-0.84) 0.008 0.56 (0.34-0.92) 0.021 0.52 (0.30-0.90) 0.020 0.51 (0.29-0.89) 0.018 0.54 (0.30-0.95) 0.032 
AF Time 1.00 (1.00-1.01) 0.699 1.00 (1.00-1.01) 0.730 1.00 (0.99-1.01) 0.699 1.00 (0.99-1.01) 0.937 1.00 (0.99-1.01) 0.978 
Energy Source (RF) 1.47 (0.81-2.65) 0.202 1.33 (0.74-2.41) 0.342 1.06 (0.54-2.07) 0.867 1.16 (0.58-2.23) 0.676 1.13 (0.57-2.24) 0.725 
Spherical LA 1.85 (1.12-3.05) 0.017 
    
1.92 (1.08-3.41) 0.026 1.87 (1.05-3.33) 0.035 
Dilated LA (LAV>100ml) 
  
1.30 (0.78-2.17) 0.311 
    
1.35 (0.74-2.32) 0.360 
Dilated LA (LAD>42mm) 
    
1.80 (0.98-3.31) 0.058 1.70 (0.92-3.17) 0.088 1.66 (0.88-3.11) 0.116 
Abbreviations as in table 1 and 2.  431 
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Figure 1.  432 
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Figure 2 435 
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Figure 3 438 
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